Full-Time

Project Manager

Clinical Supply

Posted on 5/20/2026

WEP Clinical

WEP Clinical

201-500 employees

Specialist services for early access medicines

No salary listed

Remote in UK

Remote

Category
Business & Strategy (1)
Required Skills
Inventory Management
Forecasting
Requirements
  • Bachelor's Degree (in a health or science field preferred)
  • Experience with clinical trial supply chain management, forecasting, and logistics
  • Proficiency with randomization and trial management systems
  • Experience in project management or clinical research
  • Knowledge of GMP, GDP, and regulatory requirements for clinical trial materials
  • Ability to work in a fast-paced, cross functional environment
  • Computer literacy and proficient in Microsoft Office
  • Willingness and ability travel as needed for business meetings, trainings and/or industry events
  • Strong organizational skills and attention to detail
  • Effective verbal and written communication and stakeholder management skills
  • Leadership and management skills
  • Ability to remain in a statutory position for extended periods as part of normal day-to-day activities, with reasonable adjustments considered where appropriate.
Responsibilities
  • Review trial protocols to understand clinical supply and demand requirements and develop efficient, low-risk supply strategies.
  • Forecast, monitor, and report inventory levels at depots and sites; take proactive steps to prevent shortages or overages.
  • Develop packaging and supply plans that align with project needs and minimize waste.
  • Coordinate global shipments with internal teams and local vendors, ensuring timely delivery.
  • Collaborate with Project Management, Regulatory, Logistics, and Quality teams to align supply chain with study timelines.
  • Lead internal and external meetings, including teleconferences and study Kick Offs.
  • Support development and testing of IRT systems and participate in user requirement specifications.
  • Set up, maintain, and close out CTMS and eTMF systems; conduct routine audits to ensure data accuracy and regulatory compliance.
  • Manage projects from startup to close-out, including expanded access and post-approval programs, while tracking timelines and deliverables.
  • Serve as the main contact for clients and vendors; provide updates and maintain project trackers.
  • Review and process site payments and client invoices; ensure financial accuracy and compliance with study agreements.
  • Supervise and train internal team members, provide protocol training to site staff, and support QA activities including audits and CAPAs.

WEP Clinical provides access to unlicensed or scarce medicines through Expanded Access Programs (EAP) and Managed Access Programs (MAP) for hospitals and physicians in over 60 countries. It uses a global sourcing network and handles import authorizations to obtain medicines that aren’t commercially available or are in short supply. A team of country managers and in-house pharmacists with local language skills coordinates and ships medications to healthcare providers. Revenue comes from service fees for managing access programs and sourcing medicines, with the goal of getting necessary treatments to patients quickly.

Company Size

201-500

Company Stage

N/A

Total Funding

N/A

Headquarters

Morrisville, North Carolina

Founded

2008

Simplify Jobs

Simplify's Take

What believers are saying

  • France early access can generate funded revenue before formal reimbursement.
  • Sponsor demand grows for rare diseases, oncology, and shortage-driven access pathways.
  • Cross-selling clinical trials and access services deepens accounts after the Siron acquisition.

What critics are saying

  • Named-patient programs stop when sponsors commercialize directly or choose cheaper providers.
  • Country-level regulatory refusals can block supply abruptly and eliminate program revenue.
  • Siron integration distracts management and threatens delivery quality across Europe and the Middle East.

What makes WEP Clinical unique

  • WEP Clinical specializes in expanded access, managed access, and named-patient programs.
  • January 5, 2026, Siron Clinical acquisition adds Phase I-IV trial execution capabilities.
  • Validated global sourcing and import authorization support simplify cross-border unlicensed medicine supply.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at WEP Clinical who can refer or advise you

Benefits

Health Insurance

Disability Insurance

Life Insurance

Parental Leave

Flexible Work Hours

Training Programs

Growth & Insights and Company News

Headcount

6 month growth

-16%

1 year growth

-16%

2 year growth

-16%
WEP Clinical
Jan 5th, 2026
WEP Clinical Acquires Siron Clinical

WEP Clinical acquires Siron Clinical. WEP Clinical acquires Netherlands-based CRO Siron Clinical, expanding global Phase I - IV trial delivery capabilities. Morrisville, NC, USA & London, UK - [January 05, 2026] - WEP Clinical (WEP), a full-service contract research organization (CRO), today announced the acquisition of Siron Clinical (Siron), a Netherlands-based European CRO specializing in flexible, high-quality clinical operations for biotech companies. The acquisition expands WEP's global footprint and strengthens its ability to deliver end-to-end Phase I - IV clinical trial solutions across complex, rare, and specialized therapeutic areas. Founded in 2000, Siron is headquartered in the Netherlands, with additional offices in Belgium and Germany, and clinical research professionals based across Europe and the Middle East. The company specializes in clinical operations, including project management, clinical monitoring, quality assurance, and regulatory submissions. Siron has supported more than 120 studies and is recognized for its strong track record in orphan diseases, pediatric research, and medical device trials. "This acquisition represents a significant milestone in the evolution of our CRO services. By combining WEP's global infrastructure with Siron Clinical's deep operational expertise in complex and niche indications, we can offer sponsors seamless support from early-phase development through post-approval research. Our shared culture, values, and commitment to execution excellence make this an ideal strategic fit, and we look forward to accelerating innovation and impact together." "Joining WEP gives our clients access to expanded services and global reach, while preserving the flexible, hands-on approach they value. We share WEP's commitment to quality, transparency, and patient-focused delivery, and together we will provide a more robust and scalable solution for biotech sponsors worldwide." Siron will be integrated into WEP's Clinical Trials division, enhancing WEP's existing capabilities across trial design, regulatory strategy, start-up, patient recruitment, study execution, and close-out. Clients will benefit from a larger pool of experienced CRAs, project managers, and operational leaders, alongside WEP's broader treatment access and commercialization offerings. WEP Clinical is a global Clinical Research Organization with expertise in designing, managing, and executing clinical trials across multiple therapeutic areas. With a strong focus on proactive project management, scientific integrity, regulatory compliance, and patient-centric execution, WEP supports pharmaceutical and biotech companies in bringing life-changing therapies to market efficiently and safely. Siron Clinical is a European CRO providing flexible and scalable clinical operations expertise for biotech organizations. With more than two decades of experience executing complex clinical trials, Siron delivers localized insight, hands-on support, and adaptive solutions across the clinical development journey.

WEP Clinical
Dec 1st, 2023
WEP CLINICAL HAS PARTNERED WITH PLUSULTRA PHARMA TO SUPPLY HYFTOR(R) TO PATIENTS IN EU/EEA COUNTRIES (WITH THE EXCEPTION OF GERMANY)

WEP Clinical has partnered with Plusultra pharma to supply HYFTOR(R) to patients in EU/EEA countries (with the exception of Germany).

TaiMed Biologics
Feb 3rd, 2023
TaiMed

WEP Clinical LTD (WEP), a specialist services company that works with pharmaceutical companies to help patients and physicians gain access to medicines when no other treatment options are available, has partnered with TaiMed Biologics to launch a Named Patient Program (NPP) for TROGARZO®, an IV treatment administered every two weeks for patients with muti-drug resistant HIV disease.

Yahoo Finance
Dec 21st, 2022
Y-mAbs Announces Partnership Regarding Early Access Program for DANYELZA (naxitamab-gqgk) in Europe

Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced that it has entered into a distribution agreement with WEP Clinical Ltd. (“WEP”) in connection with an early access program for DANYELZA (naxitamab-gqgk) 40mg/10mL Injection in Europe.

Y-mAbs Therapeutics, Inc.
Dec 21st, 2022
Y-mAbs Announces Partnership Regarding Early Access Program for DANYELZA (naxitamab-gqgk) in Europe | Y-mAbs Therapeutics, Inc.

Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced that it has entered into a distribution agreement with WEP Clinical Ltd. (“WEP”) in connection with an early access program for DANYELZA (naxitamab-gqgk) 40mg/10mL Injection in Europe.

INACTIVE